This report contains a summary of the analyst consensus forecasts available in the Publisher's Pharma Intelligence Center Drug Sales and Analyst Consensus Database for the Indication COVID-19. Currently there are 52 drugs indicated for COVID-19 which have analyst consensus forecasts available.
Scope
This report gives important, expert insight you won't find in any other source. 16 figures throughout the report illustrate major points and trends in COVID sales forecasts and company pipelines. This report is required reading for:- Investors that want to understand how COVID-19 has impacted Drug Revenues in the biopharmaceutical industry as well as identifying companies to invest in
- Companies that are interested in entering the COVID-19 disease space
- Large pharma companies with investment groups or BD teams looking for partnership opportunities in the COVID-19 disease space
Reasons to Buy
- Analysis of COVID-19 analyst consensus sales forecasts
- Detailed Analysis of how COVID-19 have affected analyst consensus sales forecasts for previously forecasted Drugs Detailed Analysis of how COVID-19 forecasts changed from 2020 to 2022 and what drove these changes
Table of Contents
1 COVID-19 Global Analyst Consensus Sales Forecast1.1 COVID-19 Prophylactic Vaccines with Global Analyst Consensus Sales Forecast
1.2 COVID-19 Therapeutic Drugs with Global Analyst Consensus Sales Forecast
1.3 COVID-19 Global Analyst Consensus Sales Forecast
1.4 Top Three Marketed COVID-19 Drugs with Peak Forecast: Global Analyst Consensus Sales Forecast
2 COVID-19 Prophylactic Vaccine and Therapeutic Drugs: Global Analyst Consensus Sales Forecasts
2.1 COVID-19 Prophylactic Vaccines Global Analyst Consensus Sales Forecast & Percentage Change from H1 2022 to H2 2022
2.2 COVID-19 Therapeutic Drugs Global Analyst Consensus Sales Forecast & Percentage Change from H1 2022 to H2 2022
3 COVID-19 Analyst Consensus Sales Forecast 2020 Versus 2022
3.1 COVID-19 Global Analyst Consensus Sales Forecast: Q4 2020 Versus H2 2022
3.2 Percentage Change from Q4 2020 to H2 2022 Global Analyst Consensus Sales Forecast Total COVID-19
4 BioNTech SE
4.1 Global Analyst Consensus Sales Forecast - Comirnaty
4.2 Percentage Change from H1 2022 to H2 2022 & Q4 2020 to H2 2022 Global Analyst Consensus Sales Forecast Comirnaty
5 Pfizer
5.1 Global Analyst Consensus Sales Forecast - Paxlovid
5.2 Percentage Change from H1 2022 to H2 2022 Global Analyst Consensus Sales Forecast - Paxlovid
6 Moderna
6.1 Global Analyst Consensus Sales Forecast - Spikevax
6.2 Percentage Change from H1 2022 to H2 2022 & Q4 2020 to H2 2022 Global Analyst Consensus Sales Forecast - Spikevax
7 Key Findings
8 Appendix
8.1 Methodology
8.2 Related Reports
8.3 About the Authors
8.4 About the Publisher
8.5 Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer Inc
- Moderna Inc
- Regeneron Pharmaceuticals Inc
- Gilead Sciences Inc
- AstraZeneca Plc
- Johnson & Johnson
- Eli Lilly and Co
- Vir Biotechnology Inc
- Merck & Co Inc
- CanSino Biologics Inc
- Dynavax Technologies Corp
- Celltrion Inc
- AstraZeneca Plc
- Pfizer Inc
- Novavax Inc
- Enanta Pharmaceuticals Inc
- Arcturus Therapeutics Holdings Inc
- Inovio Pharmaceuticals Inc
- Valneva SE
- Kintor Pharmaceutical Ltd
- Bavarian Nordic A/S
- Eiger BioPharmaceuticals Inc
- Sanofi
- Curevac NV
- Relief Therapeutics Holding AG
- Shionogi & Co Ltd
- Shionogi & Co Ltd
- Gilead Sciences Inc
- Humanigen Inc
- Atea Pharmaceuticals Inc
- Aridis Pharmaceuticals Inc
- Novavax Inc
- Eli Lilly and Co
- Celularity Inc
- Avalo Therapeutics Inc
- Ionis Pharmaceuticals Inc
- InflaRx NV
- Vaxart Inc
- Edesa Biotech Inc
- Immunome Inc
- Shionogi & Co Ltd
- Atossa Therapeutics Inc
- Brii Biosciences Ltd
- Histogen Inc
- I-Mab
- RedHill Biopharma Ltd
- First Wave BioPharma Inc
- TFF Pharmaceuticals Inc
- Shionogi & Co Ltd
- Atossa Therapeutics Inc
- Sinovac Biotech Ltd
